NewsBenzinga엑스바이오텍, 다기관 TASKIN 임상 2상 데이터 발표···사이먼 2단계 설계 하에 사전 지정된 1차 유효성 성공 기준 충족, 빌라마키투그 실험군 참가자의 61.3% 생존해 기준치 42명 초과 엑스바이오텍, 다기관 TASKIN 임상 2상 데이터 발표···사이먼 2단계 설계 하에 사전 지정된 1차 유효성 성공 기준 충족, 빌라마키투그 실험군 참가자의 61.3% 생존해 기준치 42명 초과 Benzinga 2026.10.19 13:03 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Overweight on First Solar, Lowers Price Target to $252 Karooooo Q2 Adj. EPS $0.57, Inline, Sales $100.292M Beat $97.720M Estimate Karooooo Affirms FY2027 GAAP EPS Guidance of $2.35-$2.44 vs $2.41 Est Lear Appoints Jared Fedele CFO, Effective March 1, 2027, Succeeding Jason Cardew Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures 'Activist Starboard Prepares To Nominate Directors At Knife River; Starboard Is Pushing Knife River To Improve Margins Or Consider A Sale, Sources Say' - Reuters News
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
'Activist Starboard Prepares To Nominate Directors At Knife River; Starboard Is Pushing Knife River To Improve Margins Or Consider A Sale, Sources Say' - Reuters News
